Agios Pharmaceuticals (Agios Pharmaceuticals) Days Payable : 1,523.38 (As of Mar. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Agios Pharmaceuticals Days Payable?

Agios Pharmaceuticals's average Accounts Payable for the three months ended in Mar. 2024 was $10.47 Mil. Agios Pharmaceuticals's Cost of Goods Sold for the three months ended in Mar. 2024 was $0.63 Mil. Hence, Agios Pharmaceuticals's Days Payable for the three months ended in Mar. 2024 was 1,523.38.

The historical rank and industry rank for Agios Pharmaceuticals's Days Payable or its related term are showing as below:

AGIO' s Days Payable Range Over the Past 10 Years
Min: 1346.67 Med: 3782.38 Max: 5310.01
Current: 1346.67

During the past 13 years, Agios Pharmaceuticals's highest Days Payable was 5310.01. The lowest was 1346.67. And the median was 3782.38.

AGIO's Days Payable is ranked better than
86.89% of 717 companies
in the Biotechnology industry
Industry Median: 147.46 vs AGIO: 1346.67

Agios Pharmaceuticals's Days Payable declined from Mar. 2023 (2,246.50) to Mar. 2024 (1,523.38). It may suggest that Agios Pharmaceuticals accelerated paying its suppliers.

Agios Pharmaceuticals Days Payable Historical Data

The historical data trend for Agios Pharmaceuticals's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Agios Pharmaceuticals Days Payable Chart

Agios Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Payable

Get a 7-Day Free Trial

3,782.38

1,798.77

Agios Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Days Payable	Get a 7-Day Free Trial															2,246.50	835.42	1,794.51	1,794.71	1,523.38

Competitive Comparison of Agios Pharmaceuticals's Days Payable

For the Biotechnology subindustry, Agios Pharmaceuticals's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Agios Pharmaceuticals's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Agios Pharmaceuticals's Days Payable distribution charts can be found below:

* The bar in red indicates where Agios Pharmaceuticals's Days Payable falls into.

Agios Pharmaceuticals Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Agios Pharmaceuticals's Days Payable for the fiscal year that ended in Dec. 2023 is calculated as

	Days Payable (A: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2022 )	+	Accounts Payable (A: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2023 )	*	Days in Period
=	( (18.616	+	9.78)	/	2 )	/	2.881	*	365
=	14.198					/	2.881	*	365
=	1,798.77

Agios Pharmaceuticals's Days Payable for the quarter that ended in Mar. 2024 is calculated as:

	Days Payable (Q: Mar. 2024 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Dec. 2023 )	+	Accounts Payable (Q: Mar. 2024 ))	/	count )	/	Cost of Goods Sold (Q: Mar. 2024 )	*	Days in Period
=	( (9.78	+	11.155)	/	2 )	/	0.627	*	365 / 4
=	10.4675					/	0.627	*	365 / 4
=	1,523.38

Agios Pharmaceuticals Days Payable Related Terms

Thank you for viewing the detailed overview of Agios Pharmaceuticals's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Agios Pharmaceuticals (Agios Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Agios Pharmaceuticals Inc (NAS:AGIO) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

AGIO:Mexico 8AP:Germany 8AP:Germany

Address

88 Sidney Street, Cambridge, MA, USA, 02139

Website

https://www.agios.com

Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development strategy for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.

Executives

Brian Goff	director, officer: Chief Executive Officer	C/O ALEXION PHARMACEUTICALS, INC, 100 COLLEGE STREET, NEW HAVEN CT 06510
Sarah Gheuens	officer: Chief Medical Officer	C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE MA 02139
James William Burns	officer: Chief Legal Officer	C/O AGIOS PHARMACEUTICALS, 88 SIDNEY STREET, CAMBRIDGE MA 02139
Jacqualyn A Fouse	director	C/O DICK'S SPORTING GOODS, 345 COURT STREET, CORAOPOLIS PA 15108
Tsveta Milanova	officer: Chief Commercial Officer	C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY SREET, CAMBRIDGE MA 02139
Cecilia Jones	officer: Chief Financial Officer	C/O LOGICBIO THERAPEUTICS, INC., 65 HAYDEN AVENUE, 2ND FLOOR, LEXINGTON MA 02421
Kaye I Foster-cheek	director	JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Washburn Theodore James Jr.	officer: Principal Accounting Officer	C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE MA 02139
Jeffrey D Capello	director	C/O NEOGEN CORP., 620 LESHER PLACE, LANSING MI 48912
Catherine E. Owen	director	1020 STONY HILL ROAD, SUITE 300, YARDLEY PA 19067
David P Schenkein	director, 10 percent owner, officer: Chief Executive Officer	C/O BLUEBIRD BIO, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Cynthia Smith	director	508 WRANGLER DRIVE, SUITE 100, COPPELL TX 75019
Rahul D. Ballal	director	116 HUNTINGTON AVENUE, 6TH FLOOR, BOSTON MA 02116
Richa Poddar	officer: Chief Commercial Officer	C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE MA 02139
Carman Alenson	officer: Principal Accounting Officer	88 SIDNEY STREET, CAMBRIDGE MA 02139